These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 33740205)

  • 81. Pathological complete response in invasive breast cancer treated by skin sparing mastectomy and immediate reconstruction following neoadjuvant chemotherapy and radiation therapy: Comparison between immunohistochemical subtypes.
    Barrou J; Bannier M; Cohen M; Lambaudie E; Gonçalves A; Bertrand P; Buttarelli M; Opinel P; Sterkers N; Tallet A; Zinzindohoué C; Houvenaeghel G
    Breast; 2017 Apr; 32():37-43. PubMed ID: 28033508
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Survival Outcomes for Patients With Clinical Complete Response After Neoadjuvant Chemotherapy: Is Omitting Surgery an Option?
    Özkurt E; Sakai T; Wong SM; Tukenmez M; Golshan M
    Ann Surg Oncol; 2019 Oct; 26(10):3260-3268. PubMed ID: 31342356
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Important considerations prior to elimination of breast cancer surgery after neoadjuvant systemic therapy: Listening to what our patients want.
    Caballero C; Piccart M
    Ann Oncol; 2020 Aug; 31(8):1083-1084. PubMed ID: 32344012
    [No Abstract]   [Full Text] [Related]  

  • 84. Breast conservation therapy after neoadjuvant chemotherapy: optimization of a multimodality approach.
    Caudle AS; Kuerer HM
    J Surg Oncol; 2014 Jul; 110(1):32-6. PubMed ID: 24623334
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Impact of chemotherapy sequencing on local-regional failure risk in breast cancer patients undergoing breast-conserving therapy.
    Mittendorf EA; Buchholz TA; Tucker SL; Meric-Bernstam F; Kuerer HM; Gonzalez-Angulo AM; Bedrosian I; Babiera GV; Hoffman K; Yi M; Ross MI; Hortobagyi GN; Hunt KK
    Ann Surg; 2013 Feb; 257(2):173-9. PubMed ID: 23291658
    [TBL] [Abstract][Full Text] [Related]  

  • 86. De-escalation of breast and axillary surgery in exceptional responders to neoadjuvant systemic treatment.
    Heil J; Pfob A; Morrow M
    Lancet Oncol; 2021 Apr; 22(4):435-436. PubMed ID: 33794203
    [No Abstract]   [Full Text] [Related]  

  • 87. Breast conservative surgery for operable invasive ductal carcinoma after neoadjuvant chemotherapy or hormonal therapy- a challenge for breast surgeon: a review based on literature and experience.
    Bobin JY; Al-Khaledi K; Ahmad J
    Gulf J Oncolog; 2011 Jan; (9):45-51. PubMed ID: 21177208
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Docetaxel followed by fluorouracil/epirubicin/cyclophosphamide as neoadjuvant chemotherapy for patients with primary breast cancer.
    Iwata H; Sato N; Masuda N; Nakamura S; Yamamoto N; Kuroi K; Kurosumi M; Tsuda H; Akiyama F; Ohashi Y; Toi M
    Jpn J Clin Oncol; 2011 Jul; 41(7):867-75. PubMed ID: 21719750
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Primary systemic therapy of breast cancer.
    Sachelarie I; Grossbard ML; Chadha M; Feldman S; Ghesani M; Blum RH
    Oncologist; 2006 Jun; 11(6):574-89. PubMed ID: 16794237
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Validation of the 21-gene test as a predictor of clinical response to neoadjuvant hormonal therapy for ER+, HER2-negative breast cancer: the TransNEOS study.
    Iwata H; Masuda N; Yamamoto Y; Fujisawa T; Toyama T; Kashiwaba M; Ohtani S; Taira N; Sakai T; Hasegawa Y; Nakamura R; Akabane H; Shibahara Y; Sasano H; Yamaguchi T; Sakamaki K; Bailey H; Cherbavaz DB; Jakubowski DM; Sugiyama N; Chao C; Ohashi Y
    Breast Cancer Res Treat; 2019 Jan; 173(1):123-133. PubMed ID: 30242578
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Short-term outcomes of neoadjuvant hormonal therapy versus neoadjuvant chemotherapy in breast cancer: systematic review and meta-analysis of randomized controlled trials.
    Huang L; Xu AM
    Expert Rev Anticancer Ther; 2017 Apr; 17(4):327-334. PubMed ID: 28271747
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Radiotherapy Issues After Neoadjuvant Chemotherapy.
    Mak KS; Harris JR
    J Natl Cancer Inst Monogr; 2015 May; 2015(51):87-9. PubMed ID: 26063895
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Talking numbers: how women and providers use risk scores during and after risk counseling - a qualitative investigation from the NRG Oncology/NSABP DMP-1 study.
    Blakeslee SB; Gunn CM; Parker PA; Fagerlin A; Battaglia T; Bevers TB; Bandos H; McCaskill-Stevens W; Kennedy JW; Holmberg C
    BMJ Open; 2023 Nov; 13(11):e073138. PubMed ID: 37984961
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Assessment and Response to Neoadjuvant Treatments in Breast Cancer: Current Practice, Response Monitoring, Future Approaches and Perspectives.
    Sabatino V; Pignata A; Valentini M; Fantò C; Leonardi I; Campora M
    Cancer Treat Res; 2023; 188():105-147. PubMed ID: 38175344
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Physician Perspectives on Reducing Curative Cancer Treatment Intensity for Populations Underrepresented in Clinical Trials.
    Rocque GB; Andrews C; Lawhon VM; Ingram SA; Frazier RM; Smith ML; Wagner LI; Zubkoff L; Wallner LP; Wolff AC
    Oncologist; 2022 Dec; 27(12):1067-1073. PubMed ID: 36215065
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Escalating de-escalation in breast cancer treatment.
    Sacchini V; Norton L
    Breast Cancer Res Treat; 2022 Sep; 195(2):85-90. PubMed ID: 35902432
    [TBL] [Abstract][Full Text] [Related]  

  • 97. De-Escalation of Breast Cancer Surgery Following Neoadjuvant Systemic Therapy.
    Wazir U; Mokbel K
    Eur J Breast Health; 2022 Jan; 18(1):6-12. PubMed ID: 35059585
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Attitudes of Australian breast cancer patients toward the secondary use of administrative and clinical trial data.
    Hutchings E; Butcher BE; Butow P; Boyle FM
    Asia Pac J Clin Oncol; 2023 Apr; 19(2):e12-e26. PubMed ID: 35723248
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Multidisciplinary Breast Cancer Clinic: A Novel Approach to Decrease Time to Intervention.
    Alongi AM; Mitchell WD; Elder EA; Rivere A; Fuhrman G
    Am Surg; 2023 Aug; 89(8):3648-3649. PubMed ID: 37132384
    [TBL] [Abstract][Full Text] [Related]  

  • 100. A conceptual framework for cautious escalation of anticancer treatment: How to optimize overall benefit and obviate the need for de-escalation trials.
    Pourmir I; Van Halteren HK; Elaidi R; Trapani D; Strasser F; Vreugdenhil G; Clarke M
    Cancer Treat Rev; 2024 Mar; 124():102693. PubMed ID: 38330752
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.